Clinical trials: Erosive Esophagitis
Erosive Esophagitis, GERD
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
The purpose of this study is to investigate the optimal dose and administration methods of CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally administered CJ-12420 to esomeprazole 40mg.
- Trial name
- NCT02028663
- Testing
- CJ-12420, Esomeprazole
- Where
- South Korea
- Volunteers
- 206 people
- Sponsor
- HK inno.N Corporation
Erosive Esophagitis(EE), Gastroesophageal Reflux Disease (GERD)
TAK-438 - Safety, Blood Levels & Effects of Repeated Doses
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of TAK-438 in healthy, non-Japanese men male subjects following a randomized, double blind, placebo controlled, sequential panel…
- Trial name
- TAK-438_107 (NCT02141711)
- Testing
- TAK-438
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Takeda
Gastric Ulcer, Duodenal Ulcer, Anastomotic Ulcer, Reflux Oesophagitis,"Non-erosive Reflux Disease, Zollinger-Ellison Syndrome
Nexium Capsules Clinical Experience Investigation
The purpose of this study is to confirm the safety profile / factors which impact safety and efficacy of Nexium capsules in daily clinical usage for the patients who have been prescribed Nexium for "gastric ulcer", "duodenal…
- Trial name
- NCT01434485
- Where
- 47 sites in Japan
- Volunteers
- 3,691 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis
The purpose of this study is to evaluate the acid-inhibitory and dose-response efficacy of TAK-438 (20 mg, 40 mg) in patients with PPI-resistant erosive esophagitis.
- Trial name
- NCT01630746
- Testing
- TAK-438
- Where
- 11 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Takeda
Erosive Esophagitis
Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis
The purpose of this study is to determine the safety of long term use of TAK-438, once daily (QD), for the maintenance treatment of healed erosive esophagitis.
- Trial name
- NCT01452776
- Testing
- TAK-438
- Where
- 32 sites in Japan
- Volunteers
- 305 people
- Sponsor
- Takeda
Erosive Esophagitis
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis
The purpose of this study is to confirm the efficacy of TAK-438, once daily (QD), compared to lansoprazole for the maintenance treatment of healed erosive esophagitis and to determine the clinical dose.
- Trial name
- NCT01459367
- Testing
- TAK-438, Lansoprazole
- Where
- 37 sites in Japan
- Volunteers
- 607 people
- Sponsor
- Takeda
GERD With Erosive Esophagitis
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 40 mg and to evaluate…
- Trial name
- NCT00206245
- Testing
- AZD0865
- Where
- 202 sites in United States, Canada and 8 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
GERD Without Erosive Esophagitis
A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.
The primary objective is to compare the efficacy between three doses of AZD0865 (25, 50 and 75 mg). The secondary objectives are to compare the efficacy between the three doses of AZD0865 and esomeprazole 20 mg and to evaluate…
- Trial name
- NCT00206284
- Testing
- AZD0865
- Where
- 202 sites in United States, Canada and 8 more
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis
The purpose of this study is to determine the efficacy of TAK-438, once daily (QD), compared to lansoprazole in patients with erosive esophagitis of Grade A to D as defined by the LA classification grading system.
- Trial name
- NCT01452698
- Testing
- TAK-438, Lansoprazole
- Where
- 32 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Takeda
Erosive Esophagitis
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis.
- Trial name
- NCT00693225
- Testing
- Omeprazole/sodium bicarbonate
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Yvonne Romero
Reflux Esophagitis (RE), Non-erosive Reflux Disease (NERD)
Analysis of GERD Symptoms Using Gastroesophageal Reflux Impact Score Questionnaire for Quality of Life
Even the patients complain GERD symptoms such as heartburn and acid regurgitation the final diagnosis could be reflux esophagitis (RE), non-erosive reflux disease (NERD) and even functional heartburn (FH).
- Conditions
- Reflux Esophagitis (RE), Non-erosive Reflux Disease (NERD), Functional Heartburn (FH)
- Trial name
- NCT01536080
- Where
- South Korea
- Volunteers
- 207 people
- Sponsor
- Seoul National University Bundang Hospital
Erosive Esophagitis, GERD
Efficacy Study of Ilaprazole to Treat Erosive Esophgitis
This study compared Ilaprazole 20mg with lansoprazole 30mg for the healing of erosive esophagitis and resolution of heartburn.
- Trial name
- NCT01509261
- Testing
- Ilaprazole, Lansoprazole
- Where
- 19 sites in South Korea
- Volunteers
- 292 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis
Esomeprazole for Treatment of GERD in Pediatric Patients
To look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease…
- Conditions
- Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis
- Trial name
- NCT00228527
- Testing
- Esomeprazole (Nexium)
- Where
- 36 sites in United States, Belgium and 2 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Erosive Esophagitis, Reflux Esophagitis
Proton Pump Inhibitor (PPI) Therapy for Newly Diagnosed Esophagitis
This study is being done to for two reasons: To learn about the effects (good and bad) esomeprazole (an FDA approved drug for reflux esophagitis) has on your esophagus when taken correctly.
- Conditions
- Erosive Esophagitis, Reflux Esophagitis, GERD
- Trial name
- EE (NCT00586963)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Mayo Clinic
Erosive Esophagitis, Reflux Esophagitis
NEXIUM® in the Treatment of Moderate and Severe Erosive Esophagitis
The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.
- Conditions
- Erosive Esophagitis, Reflux Esophagitis, Gastroesophageal Reflux Disease
- Trial name
- NCT00206180
- Testing
- esomeprazole magnesium (oral medication)
- Where
- 39 sites in United States
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis
This study looks at the healing rates in patients with Erosive Esophagitis (EE) when treated with either esomeprazole or lansoprazole
- Trial name
- NCT00641602
- Testing
- Esomeprazole, Lansoprazole
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Erosive Esophagitis
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
A study to look at the rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE).
- Trial name
- NCT00644735
- Testing
- Esomeprazole, Lansoprazole
- Volunteers
- 750 people
- Sponsor
- AstraZeneca